Table 1.
Current commonly used COVID-19 vaccines.
| Vaccine name | Vaccine type | Research and development company | Current clinical stage | Participants number | Approved time | Approved countries |
|---|---|---|---|---|---|---|
| CoronaVac | Inactivated vaccine | SinoVac-China | Phase III (being conducted) | 600 (Phase II) | February 5, 2021 | China, Brazil, Ukraine |
| BBIBP-CorV | Inactivated vaccine | SinoPharm-China | Phase II | 31,000 | April 29, 2021 | China, United Arab Emirates, Bahrain, Egypt, Australian |
| BNT16b2 | mRNA vaccine | Pfizer-the USA +BioNTech-Germany |
Phase II | 43,448 | December 2, 2020 | the UK, Canada, the USA, Bahrain, Saudi Arabia, Mexico, European Union, Japan |
| mRNA-1273 | mRNA vaccine | Moderna-the USA | Phase II | 30,000 | November 19, 2021 | the UK, European Union, Israel, Canada, the USA, Japan |
| NVX-CoV2373 | Recombinant protein vaccine | Novavax-the USA | Phase III (being conducted) | 131 | December 20, 2021 | Put on an emergency use list |
| ChAdOx1 nCoV-19 (AZD1222) | Adenovirus vector vaccine | AstraZeneca-the UK | Phase II | 11,636 | February 22, 2021 | India, Argentina, the Dominican Republic, Salvador, Mexico, Morocco, the UK, Japan |
| Ad26.CoV2.S | Adenovirus vector vaccine | Janssen-the USA | Phase III (being conducted) | 796 (Phase I/II) | March 1, 2021 | Put on an emergency use list |
| Ad5-nCoV | Adenovirus vector vaccine | CanSinoBIO-China | Phase III (being conducted) | 508 (Phase II) | September 16, 2021 | China, Ecuador, Argentina, Brazil, Malaysia |
| Sputnik V | Adenovirus vector vaccine | Gamaleya Center-Russia | Phase III | 18,794 | February 3, 2021 | Russia, Algeria, Argentina, Bolivia, Serbia, Republic of Belarus |